K061188

OCT 2 3 2006

510(k) SUMMARY

Device Name

Classification Name: Catheter, Peripheral, Atherectomy

21 CFR §870.4875, Class II

Common and Usual Name: Catheter, Peripheral, Atherectomy

Proprietary Name: SilverHawk™ Peripheral Plaque Excision System

Predicate Device

The SilverHawk[™] Peripheral Plaque Excision System (K053460) currently marketed by FoxHollow Technologies, Inc. (Redwood City, CA).

Summary

This summary of Special 510(k) safety and effectiveness is being submitted in accordance with requirements of SMDA 1990.

The SilverHawkTM\ Peripheral Plaque Excision System is intended for atherectomy of the peripheral vasculature and is not intended for use in the coronary, carotid, iliac or renal vasculature.

The SilverHawkTM Peripheral Plaque Excision System consists of two major components which are packaged separately, but used together during atherectomy procedures. The two components are the SilverHawkTM Peripheral Catheter and SilverHawkTM Cutter Driver.

The SilverHawk[™] Peripheral Plaque Excision System will be provided sterile for single-use. The catheter will be sterilized by Ethylene Oxide (ANSI/AAMI/ISO 11135), including limits for Ethylene Oxide residuals and validated to a sterility assurance level (SAL) of 10⁻⁶. The cutter driver is sterilized by Gamma Sterilization Cycle (ANSI/AAMI/ISO 11137), providing a minimum SAL of 10⁻⁶, with a minimum dose of 25kGy, using the VDmax method. The device is biocompatible per ISO-10993-1.

The SilverHawk[™] Peripheral Plaque Excision System with the additional clinical contraindication statement is identical in material of construction, overall design, intended use, and safety and efficacy to the predicate device.

The SilverHawk[™] Peripheral Plaque Excision System with the additional clinical contraindication statement is considered substantially equivalent to the SilverHawk[™] Peripheral Plaque Excision System (K053460).

Contact:

Date: 18 October 2006

Melissa Murphy Regulatory Compliance Manger FoxHollow Technologies, Inc. 740 Bay Road Redwood City, CA 94063 (650) 421-8579



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

OCT 2 3 2006

FoxHollow Technologies, Inc. c/o Ms. Melissa Murphy Senior Regulatory Specialialist 740 Bay Road Redwood City, CA 94063

Re: K061188

SilverHawk™ Peripheral Plaque Excision System

Regulation Number: 21 CFR 870.4875

Regulation Name: Peripheral Atherectomy Catheter

Regulatory Class: Class II (Two)

Product Code: MCW Dated: October 11, 2006 Received: October 13, 2006

Dear Ms. Murphy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Donna R. Luchmer

Bram D. Zuckerman, M.D.

Division of Cardiovascular Devices
Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): . K061188 .

Device Name: SilverHawkTM Peripheral Plaque Excision System

Indications For Use:			
The SilverHawk TM Peripheral			
peripheral vasculature. The cavasculature.	atheter is not intended for us	se in the coronary,	carotid, iliac or renal
vasculature.			
Prescription UseX	AND/OR	Over-The-C	Counter Use
(Part 21 CFR 801 Subpart D)			7 Subpart C)
		`	,
(PLEASE DO NOT WRITE I		PINITIE ON ANOT	THEO DACE TE
NEEDED)	DELOW THIS LINE-CONT	.INCE ON ANOT	HER I AGE II
Concurr	ence of CDRH, Office of	Device Evaluation	on (ODF)
Concurr	once of Chief, Office of	Device Evaluation	on (ODL)
	puma R. Lod	mes	
	(Division Sign-Off)		
	Division of Cardiovasc	ular Devices	
	510(k) (vumber <u>K06</u>	1188	Page 1 of _1_